Evidence map›Paper›PMID 42369662›Full record

ArticleiScience2026

Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.

Jaume Barcelo, Yumiko Teigen, Joshua Alexander James Martin, Samantha George, Dipanwita Das, Joanne Sewell, Anna Perdrix-Rosell, Findlay Bewicke-Copley, Ritobrata Ghose, William Yang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jaume BarceloCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Yumiko TeigenCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Joshua Alexander James MartinCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Samantha GeorgeCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Dipanwita DasCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Joanne SewellCentre for Tumor Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, UK.
Anna Perdrix-RosellTumor-Host Interaction Laboratory, The Francis Crick Institute, London, UK.
Findlay Bewicke-CopleyCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Ritobrata GhoseCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
William YangPrecision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Rachel BroughPrecision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Andrew ClearCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Wencke WalterMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Ilaria MalanchiTumor-Host Interaction Laboratory, The Francis Crick Institute, London, UK.
John G GribbenCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Louie N van de LagemaatCentre for Genome Enabled Biology and Medicine, University of Aberdeen, Aberdeen, UK.
Kamil R KrancThe Institute of Cancer Research, Sutton, London, UK.
Christopher J LordPrecision Oncology Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Ana Rio-MachinCentre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Oscar MaiquesCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Jude FitzgibbonCentre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Victoria Sanz-MorenoCytoskeleton and Cancer Metastasis Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although Rho kinase (ROCK) has been studied in tumor progression, the reliance of some cancer cells on ROCK-Myosin II for survival remains poorly understood. Using systematic analysis of ROCK inhibitor sensitivity in hundreds of cancer cell lines, we find that ROCK inhibition reduces survival of highly de-differentiated, invasive cancer cells from solid tumors. Transcriptomic analysis reveals enrichment in epithelial-to-mesenchymal transition, migration, proliferation, and inflammation genes, with reduced expression of differentiation and cell-cell junction genes like E-cadherin (CDH1). Acute myeloid leukemia (AML) shows high ROCK inhibitor response among hematological malignancies. Using

Indexed as

cancertherapeuticstranscriptomics

Identifiers

PMID42369662
PMCPMC13309995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.